Le Lézard

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (w…

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the ...